Education and Training
Topical Itraconazole in Treating Patients With Basal Cell Cancer
This phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. Itraconazole gel may help to treat basal cell tumors in patients.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Itraconazole
- other: Placebo
Eligibility
Inclusion Criteria:
- The subject must sign and date all informed consent statements; children will sign the
assent form and their guardian will sign the consent form
- The subject must be willing to apply the medications twice daily for 1 month
- The subjects must have at least four BCCs in non-cosmetically sensitive sites
- For women of child-bearing potential, a negative urine pregnancy test
- Women of child-bearing potential are expected to use an effective method of birth
control to prevent exposing a fetus to potentially dangerous agent with unknown risk
- For male patients with female partners of childbearing potential, agreement to use
adequate contraception while you are participating in the study and 1 month after
applying your last dose
Exclusion Criteria:
- Pregnancy or breast-feeding
- History of congestive heart failure or other findings of ventricular dysfunction
- History of current evidence of malabsorption or liver disease
- Current immunosuppression or taking immunosuppressive drugs
- Taking oral itraconazole
- Taking any medication known to affect hedgehog (HH) signaling pathway
- The subject has used topical or systemic therapies that might interfere with the
evaluation of the study medication during the study; specifically these include the
topical use to the study tumors of: glucocorticoids (ii) retinoids (e.g., etretinate,
isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically (iii)
alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to more than 5% of the skin
during the six months prior to study entry (iv) 5-fluorouracil or imiquimod; also -
treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling
within 60 days to starting study medication
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting